GlassScriptPhysician profile
Thomas W Froehlich
NPI 1164512414
$3,046.42
in general payments reported to CMS, 2019-2025
15 companies · $59.52 in 2025
The $59.52 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $39.95 · 2020: $2,620 · 2021: $35.77 · 2022: $33.79 · 2023: $107 · 2024: $150 · 2025: $59.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $316.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,620.00 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $60.62 | 2023-2024 | Imfinzi, Airsupra |
| Merck Sharp & Dohme LLC | $48.48 | 2023 | Keytruda, Lynparza, Welireg |
| Janssen Biotech, INC. | $40.71 | 2024-2025 | Erleada, Balversa, Akeega |
| Genentech, INC. | $39.95 | 2019 | |
| Seagen INC. | $37.51 | 2022-2023 | Tukysa |
| Incyte Corporation | $36.32 | 2023-2024 | Jakafi, Pemazyre, Monjuvi |
| Abbvie INC. | $31.96 | 2024-2025 | |
| Karyopharm Therapeutics INC. | $24.16 | 2024 | Xpovio |
| Tersera Therapeutics LLC | $21.66 | 2025 | Xermelo |
| Eisai INC. | $20.54 | 2024 | |
| Blue Earth Diagnostics | $19.38 | 2021 | |
| Deciphera Pharmaceuticals INC. | $16.39 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.40 | 2022 | |
| Taiho Oncology, INC. | $13.34 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Froehlich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.